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Human immunodeficiency virus type 1 (HIV-1) exists as a complex population of multiple genotypic variants
in persons with chronic infection. However, acute HIV-1 infection via sexual transmission is a low-probability
event in which there is thought to be low genetic complexity in the initial inoculum. In order to assess the viral
complexity present during primary HIV-1 infection, the V1/V2 and V3 variable regions of the env gene were
examined by using a heteroduplex tracking assay (HTA) capable of resolving these genotypic variants. Blood
plasma samples from 26 primary HIV-1-infected subjects were analyzed for their level of diversity. Half of the
subjects had more than one V1/V2 viral variant during primary infection, indicating the frequent transmission
of multiple variants. This observation is inconsistent with the idea of infrequent transmission based on a small
transmitting inoculum of cell-free virus. In chronically infected subjects, the complexity of the viral populations
was even greater in both the V1/V2 and the V3 regions than in acutely infected subjects, indicating that in spite
of the presence of multiple variants in acute infection, the virus does pass through a genetic bottleneck during
transmission. We also examined how well the infecting virus penetrated different anatomical compartments by
using the HTA. Viral variants detected in blood plasma were compared to those detected in seminal plasma
and/or cerebral spinal fluid of six individuals. The virus in each of these compartments was to a large extent
identical to virus in blood plasma, a finding consistent with rapid penetration of the infecting variant(s). The
low-probability transmission of multiple variants could be the result of transient periods of hyperinfectious-
ness or hypersusceptibility. Alternatively, the inefficient transfer of a multiply infected cell could account for
both the low probability of transmission and the transfer of multiple variants.
Characterization of the earliest stage of human immunode-
ficiency virus type 1 (HIV-1) infection, primary infection, is
critical for gaining a better understanding of HIV-1 pathogen-
esis. Determining what variants are transmitted and what fac-
tors, if any, affect transmission will greatly aid the development
of vaccines and other prophylactic therapies (such as microbi-
cides). Primary infection studies may also lead to a better
understanding of the role of innate host defense.
Primary infection can be roughly subdivided into two phases:
acute and early. Peak viremia is reached and resolved during
the acute phase while the virus replicates initially in the ab-
sence of immune response. Primary infection symptoms begin,
on average, 2 weeks after infection (3, 31, 45, 54), most likely
the result of the initial immune response. During early primary
infection, the immune response matures leading to serocon-
version and a steady state of HIV-1 replication (4, 6, 8, 23, 28,
38, 63, 66, 67). Primary infection ends with seroconversion and
stabilization of the Western blot pattern (7, 31). Identifying
subjects during primary infection is difficult but critical to its
study. The absence of HIV-1 antibodies as measured by en-
zyme-linked immunosorbent assay (ELISA; seronegative) de-
fines the acute primary infection stage. The detection of evolv-
ing antibody specificity, measured by Western blotting, is an
indicator of early primary infection. Western blot antibody
specificities typically become diagnostic within 1 to 2 weeks of
ELISA positivity (19).
Transmission probabilities associated with the most com-
mon HIV-1 exposures are relatively low (18, 22, 58), which a
priori would be expected to create a genetic bottleneck that
would result in the infecting variant being genetically less com-
plex than the swarm of donor virus strains. Transmission can
occur from either cell-free virus (e.g., infection via plasma-
derived blood products) (34) or from cell-associated virus (e.g.,
infected cells in semen) (68). However, in most cases it is not
clear which of these forms of virus is transmitted.
Studies of viral diversity during primary infection have gen-
erated variable results. The presence of homogeneous (1, 11,
20, 27, 37, 39, 43, 44, 55, 56, 63, 64, 67) or heterogeneous (10,
14, 16, 25, 29, 30, 32, 36, 42, 48, 53, 57, 60, 65, 68) virus
populations have been documented. Evidence for differences
in viral heterogeneity during primary infection based on sex
has also been reported (33, 47) but not seen consistently (36).
These discrepancies are in part explained by the different re-
gions of the viral genome that were compared, the different
modes of transmission among populations, the different defi-
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nitions of primary infection that were used, and different cri-
teria by which viral populations were categorized as homoge-
neous versus heterogeneous.
We assessed viral diversity during primary infection by het-
eroduplex tracking assay (HTA), which resolves distinct geno-
types in a gel-based assay (9, 12). Heterologous probes were
used to enhance the detection of nucleotide differences of
2% between viral variants as described by Kitrinos et al. (26).
The HTA is capable of accurately quantitating variants con-
tributing as little as 3% to the total viral population (49). We
applied this technology to reveal the presence of multiple co-
existing variants of the V1/V2 and V3 variable regions of the
viral env gene within infected people (26, 40, 41). Here we
report studies to examine the complexity of the viruses present
in the blood plasma of 26 subjects in a primary infection co-
hort. All subjects in the present study were infected through
sexual contact. All but one subject was estimated to have ac-
quired HIV-1 fewer than 90 days prior to sampling. Approxi-
mately 50% of the subjects harbored multiple viral variants, a
result inconsistent with a low transmission probability from an
inoculum consisting solely of cell-free virus. The initial viral
populations present in the seminal plasma (SP) and/or cerebro-
spinal fluid (CSF) were also examined in a subset of subjects.
Significant penetrance of the transmitted variants was observed
in these compartments as early as 1 month after infection.
MATERIALS AND METHODS
Subjects. The 26 subjects in the present study were part of a primary HIV-1
infection cohort enrolled at the University of North Carolina–Chapel Hill, Duke
University, and Emory University. All but one of the subjects were identified
after presentation with symptoms of an acute retroviral syndrome. The number
of days postinfection was estimated by adding 2 weeks to the date of symptom
onset; for one asymptomatic subject, a unique sexual exposure was reported, and
transmission was confirmed by phylogenetic analysis. A negative HIV-1 antibody
test within 30 days of diagnosis or an evolving Western blot pattern was necessary
for inclusion, except for subjects Z04 and Z09, who were included based on
interview and disease symptoms. Blood plasma samples were collected for all
subjects, whereas CSF and/or seminal samples were examined where available.
Subject characteristics are presented in Table 1. The average log10 viral load was
5.6, and the range was 3.7 to 7.3. The average CD4 count was 518 cells/l (range,
128 to 1,161). All samples were collected with informed consent under an
Institutional Review Board-approved protocol.
The 17 subjects with established HIV-1 infection were part of a study at the
University of North Carolina–Chapel Hill to assess the effects of antiretroviral
treatment on the development of HIV-1-associated neurological dysfunction.
The average log10 viral load was 4.9 (range, 4.2 to 6.4). The average CD4 count
was 243 cells/l (range, 10 to 500). All blood plasma samples were collected and
analyzed in the absence of ongoing antiretroviral therapy treatment and with
informed consent.
RNA extraction. RNA was extracted from 140 l of blood plasma, CSF, or SP
by using the QIAamp viral RNA minikit as described by the supplier (Qiagen,
Valencia, Calif.) with a final 60-l elution volume. Samples with viral RNA loads
of 10,000 copies/ml were concentrated by centrifugation of 1 ml of sample at
25,000  g for 1.5 h at 4°C before RNA extraction. The virus pellet was resus-
pended in 140 l of its supernatant, and RNA was extracted as described above.
RT-PCR. The V1/V2 region of the HIV-1 env gene was reverse transcribed by
using a modified Titan One-Step RT-PCR system (Roche Molecular Biochemi-
cals). The Titan One-Step RT-PCR system protocol was as described in Kitrinos
et al. (26). Briefly, the cDNA synthesis reaction consisted of 1 Titan RT-PCR
buffer, 15 pmol of V2 primer, a 1 mM concentration of each deoxynucleoside
triphosphate (Amersham Pharmacia), 5 mM dithiothreitol, 10 U of RNase in-
hibitor (Roche Molecular Biochemicals), 14 U of avian myeloblastosis virus
(AMV) reverse transcriptase (RT) (Roche Molecular Biochemicals), and 5 to 10
l of eluted viral RNA in a total volume of 20 l. cDNA synthesis reactions were
incubated at 42°C for 30 min and then at 95°C for 5 min to inactivate the AMV
RT. A 30-l PCR mix consisting of 1 Titan RT-PCR buffer, 15 pmol of V1
primer, 5 mM dithiothreitol, and 1.7 U of Titan or Expand enzyme was added to
each 20-l cDNA synthesis reaction for a final volume of 50 l. PCR tempera-
tures and cycle numbers were as described by Kitrinos et al. (26).
V3 RT-PCR products were generated by using the Expand One-Tube RT-
PCR kit (Roche) modified as described by Nelson et al. (41). The Expand Kit
reactions consisted of 5 to 10 l of eluted RNA, 1 Expand HF Buffer, 2.5 mM
MgCl2, 0.5 mM concentrations of each deoxynucleoside triphosphate, 15 pmol of
V3R5 primer, and 12 U of AMV RT in a total volume of 20 l. cDNA synthesis
reverse transcription reactions were incubated at 42°C for 30 min, followed by 2
min at 99°C to inactivate the AMV RT. A 30-l PCR consisting of 1 Expand
HF buffer, 2.5 mM MgCl2, 15 pmol of V3L4 primer, and 2.6 U of Expand HF
enzyme mix was then added to the 20-l cDNA synthesis reaction for a final
volume of 50 l. The following PCR program was used to amplify the V3
products: 1 cycle of 95°C for 2 min and 45 s, 52°C for 45 s, and 72°C for 1 min,
followed by three sets of 10 cycles of 95°C for 45 s, 52°C for 45 s, and 72°C for
1 min (with an additional minute for each set of 10 cycles). The last cycle had a
72°C extension for 7 min.
The gag fragment generated for vaccine analysis was obtained through RT-
PCR of two separate primers jointly covering the p17 and p24 region (nucleo-
tides 2546 to 3515, HXB2 numbering). The G1up (5-GGGTGCGAGAGCGT
CAGTATTAAG-3) and G1dn (5-TGAAAACATGGGTATTACTTCTGGG
C-3) primers amplify nucleotides 2545 to 3041. The G2up (5-ACATCAGGC
CATATCACCTAGAAC-3) and G2dn (5-TCCAATTTTTTACCTCCTGTGA
AGC-3) primers amplify nucleotides 2932 to 3515. The two env fragments were
amplified with the E1 and E2 primer sets. The E1Bup (5-CATACATTATTG
TGCCCCGGCTGG-3) and E1dn (5-CGTTACAATTTCTGGGTCCCCTCC-







Z01 7 F 4.5  I HT
Z02 4 M 5.5  I HT
Z03 5 M 5.3 4.3  I HM
Z04 27 M 5.3   HM
Z05 4 M 7 NA  HT
Z06 6 M 5.7  I HM
Z07 10 M 3.7 NA I HM
Z08 7 M 5.5  I HM
Z09 8 M 4.4 3.1  NA HM
Z10 10 M 5.3 3.8  I HM
Z11 10 M 6.1 3.1 5.9  I HM
Z12 8 M 5.1  I HM
Z13 10 M 4.7 3.1  I HT
Z14 3 M 5.8   HM
Z15 12 F 5.3  I HT
Z16 6 M 6.2 NA I HM
Z17 5 M 6.4  I HM
Z18 5 M 6.5 3.3 NA  HM
Z20 4 M 7.1 3.8f 4.3  I HM
Z23 6 M 5.3 NA NA HM
Z24 5 M 7.3  I HT
Z25 10 M 4.7  I HM
Z26 6 M 6.1 NA  HM
Z27 5 M 5.3 3.8 NA NA HT
Z29 5 M 5.7 3.8 3.7g  I HM
Z30 5 F 6.2  
a All data refer to subject samples used in this study and not necessarily
samples used to identify eligible study subjects. All compartment samples are
matched for time unless otherwise noted. WPI, weeks post-infection; NA, not
applicable; M, male; F, female.
b That is, the log10 copies of viral RNA/milliliter of blood plasma, CSF, or
seminal plasma.
c Reactivity to sensitive HIV-1 ELISA (EIA).
d Reactivity to HIV-1 Western blot (WB). , Negative; I, incomplete; ,
positive.
e Mode of transmission: HT, heterosexual; HM, homosexual.
f Sample from 1 week before blood plasma and seminal plasma samples were
obtained.
g Sample from 1 week after blood plasma and CSF samples were obtained.
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3) primers span the C2, V3, and C3 regions (nucleotides 6815 to 7346, HXB2
numbering). The E2Bup (5-AAACATGTGGCAGGAAGTAGGAAAAGC-
3) and E2dn (5-GTGCAAATGAGTTTTCCAGAGCAACC-3) cover the C-
terminal of C4, V5, C5, and gp41 N terminus (nucleotides 7626 to 7986, HXB2
numbering). Both the gag and env cDNA fragments were generated by using the
Expand kit under the same conditions described for the V3 region except that 2.0
mM MgCl2 was used for the env fragments. The following PCR program was
used for amplification in a Stratagene 40 Robocycler: 1 cycle of 94°C for 2 min
and 45 s, 53°C for 45 s, and 68°C for 1 min; 40 cycles of 94°C for 45s, 53°C for
45 s, and 68°C for 1 to 4 min (1-min increase every 10 cycles); and 1 cycle of 94°C
for 45 s, 53°C for 45 s, and 68°C for 7 min.
HTA. V1/V2-HTAs were carried out by using a single-strand 35S-labeled probe
derived from either the HIV-1 JR-FL or Ba-L cloned genome as described by
Kitrinos et al. (26). An aliquot of 8 l of unpurified RT-PCR product was
combined with 1 l of probe, 1 l of 10 annealing buffer (1 M NaCl, 100 mM
Tris-HCl [pH 7.5], 20 mM EDTA), and 0.1 M concentrations of V1 and V2
primers in a total volume of 10 l. The probe and duplex PCR product were
denatured at 95°C for 2 min, followed by a 5-min incubation at room tempera-
ture to allow formation of heteroduplexes. Heteroduplexes were resolved by
electrophoresis through a 6% nondenaturing polyacrylamide gel (acrylamide-
bisacrylamide [37.5:1]) in 1 Tris-borate-EDTA buffer. Dried gels were exposed
to X-ray film and a phosphorimaging screen (Molecular Dynamics).
V3-HTAs were carried out as described by Nelson et al. (40, 41). Briefly,
annealing reactions were set up as in the V1/V2-HTA but with either a clade B
V3 probe (JN27) and the V3L4 primer or the clade C V3 probe (JN33) and the
V3R5 primer. Screening by HTA with a clade B R5-consensus sequence probe
(JN27) detects variants with sequence changes away from the R5-like consensus
(41). Sequence analysis can then be used to identify variants with changes
indicative of CXCR4 usage. Additional screening with a heterologous clade C
V3-HTA probe (JN33) enhances the detection of point mutations that distin-
guish V3 genotypic variants. The heteroduplexes were resolved by electrophore-
sis in a 12% polyacrylamide gel under the same conditions as the V1/V2-HTA.
Dried gels were exposed to X-ray film and a phosphorimaging screen. All am-
plifications and HTA analyses were repeated to document the presence of the
same variants at the same relative concentration as a control to validate the
quality of sampling. All samples that displayed a single genotypic variant had
RNA levels comparable to the samples that gave acceptable sampling of multiple
variants.
Sequence analysis. V1/V2 RT-PCR products were gel purified by using a
Qiagen gel purification kit. V3 RT-PCR products were purified by using a
QIA-quick PCR purification kit (Qiagen). Purified products were either directly
sequenced or cloned by using the pT7Blue-3 Perfectly Blunt cloning kit (Nova-
gen). Individual clones were amplified by colony PCR with the appropriate
primers and screened by HTA with the appropriate probe. Two to ten clones
representing each variant were selected for sequencing. Sequences were deter-
mined by using ABI dye terminator sequencing (Perkin-Elmer Corp.) and ana-
lyzed with MacVector 7.0 (Genetics Computer Group, Madison, Wis.).
Uncorrected V1/V2 nucleotide pairwise distances were calculated with DIS-
TANCES (Genetics Computer Group (GCG) Wisconsin package, version 10.1-
GCG). The sequence relatedness of V1/V2 clones was further analyzed by
neighbor-joining. Length differences were removed from sequence alignments
used in phylogenetic analysis.
Bulk sequencing of the G1, G2, E1, and E2 primer set products was obtained
by direct sequencing of purified RT-PCR products by using ABI dye terminator
sequencing (Perkin-Elmer Corp.). The two gag fragments from each subject were
aligned by using GCGSEQALIGN and combined into one sequence spanning
nucleotides 2546 to 3515 (HXB2 numbering). Analysis of the two env sequences
was performed by concatenating the sequence fragments representing each iso-
late. The phylogenetic analysis of the gag region was performed by a neighbor-
joining tree.
Sets of sequences representing subtype B isolates from the United States (123
and 133 sequences spanning the above regions of gag and env sequences, respec-
tively) were obtained from the Los Alamos HIV Sequence Database. A consen-
sus sequence was generated for each fragment from multiple sequence align-
ments created with GCG Pileup. Amino acid positions were identified by
aligning this consensus sequence with the corresponding HIV-1 HXB2 protein
sequence. Amino acid sequence identity scores between all pairs of unaligned
sequences were determined by using GCG Gap.
Nucleotide sequence accession number. The sequences reported here have
been submitted to GenBank under accession numbers AY705242 through
AY705348.
RESULTS
Identification of subjects. The primary infection cohort of 26
subjects includes 3 (11%) females and 23 (89%) males. Likely
modes of transmission established by patient history include
heterosexual (n  7), homosexual (n  18), and oral-genital
(n  1). The mode of transmission was not known for one sub-
ject (Z30). Subject characteristics are given in Table 1. HIV-
1-specific antibodies, measured by ELISA, were absent at
baseline in subjects Z14, Z24, and Z30. The remaining subjects
had evolving Western blots except for subjects Z04 and Z09. In
a controlled study of primary infection in macaques, all ani-
mals resolve their viremia by 7 weeks postinfection (52). Sub-
jects estimated as being at 7 weeks postinfection had signif-
icantly higher viral loads than those at 7 weeks postinfection
(P  0.001 [Wilcoxon rank sum test]) (Fig. 1), supporting
both the primary infection diagnosis and timing estimates.
A cohort of 17 chronic stage subjects enrolled at the Uni-
versity of North Carolina–Chapel Hill to assess the effects of
retroviral treatment on the development of HIV-1 associated
cognitive disorders was used for comparison. All samples as-
sayed were obtained at times when the subjects were not receiv-
ing treatment. This cohort consisted of 14 males and 3 females.
Virus complexity during primary infection. The number of
coexisting viral variants within subjects was assessed by analyz-
ing the variable regions 1 and 2 (V1/V2) of the HIV-1 env gene
by HTA. A single V1/V2 viral variant was detected in approx-
imately one-half of primary infection subjects (12 of 25), with
two to five variants being detected in the remainder (mean 
2.0, median  2) (Fig. 2). The complexity of the V1/V2-HTA
pattern obtained from primary infection subjects was com-
pared to that seen in the 17 chronic-stage subjects. Only one
subject from the chronic cohort displayed a single V1/V2 vari-
ant, with the remainder having 2 to 10 variants (mean  5.1,
median  4) (Fig. 3). Thus, although the complexity of the vi-
rus population was reduced in the primary infection cohort
FIG. 1. Relationship between viral load and estimated time since
infection. Log10 viral load (copies/milliliter) for the sample analyzed is
plotted versus the estimated time after infection, assuming infection
was 2 weeks prior to the onset of symptoms of acute infection. A
vertical line is included at week 7 to indicate groups of subjects staged
to before or after this time. Filled symbols are subjects whose virus
showed a single V1/V2 variant (as assessed by HTA); open symbols are
subjects whose virus showed multiple V1/V2 variants.
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relative to the chronically infected cohort, ca. 50% of primary
infection patients had multiple variants present.
There was no statistically significant difference between the
distribution of the number V1/V2 variants per person in pri-
mary infection samples obtained between 3 to 7 weeks and 8 to
14 weeks postinfection (P  0.115) (Fig. 3). There was no
relationship between viral diversity and the detection of early
antibodies (not shown). Diversity was evident in one of the
three ELISA-negative subjects (Z14, Z24, and Z30), with Z30
displaying three variants. These data indicate that the V1/V2-
HTA patterns provide one measure of the complexity of the
virus early after transmission and that multiple genotypic vari-
ants are frequently present.
Multiple V1/V2 variants were not equally distributed across
the different modes of transmission (Fig. 2). Homosexual trans-
mission resulted in infection with a single variant in only 6 of
18 (33%) instances, while heterosexual transmission to a male
resulted in only single variants being transmitted (5 of 5) (P 
0.014 [Fisher exact test]). In the two females infected by het-
erosexual contact, one (Z15) had a single variant and the other
(Z30) displayed multiple variants.
Intrapatient genetic distances and detection of dual infec-
tions. The presence of multiple V1/V2 variants during primary
infection could be the result of multiple independent transmis-
sion events occurring in close succession. In these instances,
the genetic distance between viral variants would be greater
than that expected within a single subject. The individual
V1/V2 viral variants were cloned, and the genetic distance
was calculated from a subset of subjects representing the
transmission of either single (Z06 and Z24) or multiple
(Z03, Z10, Z11, Z16, Z18, Z25, Z26, and Z30) variants.
Subjects were selected from both before and after the
7-week division. Either 6 or 10 clones from each of the two
independent RT-PCRs were cloned from Z06 and Z24, respec-
tively. All clones from Z06 (12 of 12) were identical to the
nucleotide level. In subject Z24, 18 of 20 clones were identical
to the nucleotide level, with the remaining 2 each having a
single nucleotide change. Thus, the variability within an HTA
band in these two primary infection subjects that had single
HTA variants is essentially zero and therefore represents ho-
mogeneous populations. Similarly, when multiple variants
were transmitted, sequence analysis of clones representing in-
FIG. 2. V1/V2-HTA patterns of subjects during primary HIV-1 infection. (A) Control lanes with the probes for V1/V2 diversity analysis (JR-FL
and Ba-L). Probes were run alone with or without the denaturing step or with their own or alternate probe’s PCR product. The asterisks indicate
the single-stranded probe, and the lower bands are the probe homoduplex. (B) Blood plasma samples were used as the source of viral RNA which
was then used as a template to amplify the V1/V2 region of env using PCR. Heteroduplexes were formed with either the JRFL or BAL V1/V2
probe, which were then resolved in a polyacrylamide gel. The identifier of each subject is shown above the lane. The band with the asterisk
represents the position of the single-stranded HTA probe. The weeks postinfection (WPI) and the numbers of V1/V2 variants detected (#) are
indicated at the bottom of each lane.
FIG. 3. Comparison of number of V1/V2 variants detected by HTA
with time after infection. Each datum point represents one subject
from the primary infection cohort. The estimated time postinfection is
plotted versus the number of V1/V2 variants detected for the subject
(Fig. 2). Subjects in the primary infection cohort are compared to a
separate group of subjects during the chronic stage of their HIV-1
infection. Although not resolved in the figure, there are nine individ-
uals identified with single variants prior to week 7.
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traband comparisons showed that 90% of the clones were
either identical to or differed by a single nucleotide from the
inferred consensus sequence for that band, again indicating
that each HTA variant largely represented a clonal infection.
The genetic distances between HTA variants within a sub-
ject (interband) were calculated in the subset of subjects ex-
amined with multiple variants. Identified variants were cloned
and sequenced. The majority (six of eight) of subjects had
interband genetic distances for these V1/V2 segments that
were consistent with the transmission of multiple variants from
a single donor (Fig. 4), with interband distances ranging from
0.23 to 7.3% (mean of 2.4%). However, the interband dis-
tances in two subjects (Z25 and Z26) were indicative of dual
infection (Fig. 4). Subject Z25 had an interband genetic dis-
tance of 21%, suggesting dual infection from two independent
transmission events, each resulting in the transfer of a single
variant. The interband genetic distances in subject Z26 ranged
from 2 to 19%, suggesting one transmission event of a single
variant and another of multiple variants.
Viral tropism during primary infection. Viral cell tropism
and V3 diversity at primary infection can be inferred from
V3-HTA and sequence analysis. The V3-HTA data for the 26
primary infection subjects are shown in Fig. 5. The HTA probe
(clade B or C) revealing the greatest number of variants is
shown. Eighty-five percent of the subjects (22 of 26) had one
detectable V3 variant, with no one having more than two
variants. All subjects with two V3 variants also exhibited mul-
tiple V1/V2 variants. In contrast, a mean of 2.5 V3 variants was
detected in the chronic cohort (median  2, range  1 to 4)
(data not shown).
Sequence analysis of either the bulk PCR product or clones
of the PCR products showed that all but one subject harbored
R5-like virus (not shown). Subject Z14 had the characteristic
X4-like 11R substitution within V3. CXCR4 usage was con-
firmed by growth of a virus isolate from Z14 peripheral blood
cells in MT2 cells (not shown).
Characterization of linked transmissions. Contact tracing
revealed that primary infection subject Z10 was the source of
virus for subject Z11. Only 5 days separate their calculated day
of infection. The direction of transmission is supported by
delayed seroconversion in subject Z11 relative to Z10. Al-
though this linked transmission is not apparent as comigrating
bands in the V1/V2 HTA analysis, sequence analysis of Z10
and Z11 V1/V2 clones revealed significant sequence similarity
outside the length-variable regions (not shown). Sequence dif-
ferences within the V1/V2 length-variable regions of Z10 and
Z11 are consistent with their different V1/V2-HTA patterns. In
the V3 region, only the lower of the two Z10 V3 variants was
detectable in Z11 (Fig. 5). The V3 sequence of this variant was
FIG. 4. Phylogenetic analysis of V1/V2 clones. RT-PCR products
from separate reactions independently cloned after gel purification.
Variant clones were identified by HTA screening. Where possible, at
least two independent clones of each variant were sequenced. For two
subjects, Z06 and Z24, the single variant was independently cloned and
sequenced 6 to 10 times from each RT-PCR product. The neighbor-
joining tree was made with aligned sequences with gaps ignored. All
sequences are from the blood. Identifiers indicate subject (e.g., Z10),
clone (e.g., g3), and HTA band (e.g., 0.1, 0.2, etc.), respectively. For
subjects Z06 and Z24, which each had a single variant, the HTA band
number is indicated as “0.” For these two subjects, the number of
clones with identical sequences is shown in parentheses.
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identical in Z10 and Z11, as were the bulk protease and RT
sequences (not shown). Phylogenetic analysis confirmed this
link, with Z10 and Z11 sequences from env and gag being more
closely related to each other than to other clade B primary
infection sequences (Fig. 4 and 6). The sequence relatedness
supports the contact tracing, whereas the HTA analysis indi-
cates the potential for contraction of the viral population at
transmission.
Unexpectedly, subjects Z08 and Z09 had very similar V1/
V2-HTA patterns. Further interviews indicated a recent shared
sexual partner. The translated V1/V2 sequences of Z08 and
Z09 are identical, even through the length-variable regions. The
nucleotide sequence varies by a single synonymous change.
Subjects Z08 and Z09 also share an identical V3 variant by
both HTA and sequence analysis of the PCR product. Finally,
bulk sequencing of PCR product spanning the majority of the
gag gene showed close branching (Fig. 6). The presence of such
closely related V1/V2 (Fig. 4), V3 (Fig. 5), and gag variants
(Fig. 6) suggests a common source of infecting virus and, in
these cases, the transmission of the same variant.
Analysis of compartmentalization during primary infection.
Paired blood plasma, SP, and/or CSF samples were examined
in both the V1/V2 and the V3 env regions by HTA in a subset
of subjects to determine whether compartmentalization be-
tween these regions exists during primary infection. Virus was
detected in these compartments in all cases examined. This
analysis included six semen samples and five CSF samples from
31 to 72 days postinfection. Thus, it appears the infecting virus
can populate these compartments quickly after infection.
The V1/V2-HTA for the blood/SP comparison for six sub-
jects is shown in Fig. 7. Evidence for compartmentalization is
present only in subject Z03, with shared variants present at
differing relative abundance. The difference seen in Z03 was
confirmed by quantitative phosphorimager analysis. Phosphor-
imager data were collected in duplicate by analyzing the HTA
banding pattern from two separate RT-PCRs. In the blood, the
fastest-migrating variant constitutes 75% (averages of 76 and
74%) of the total viral population, and the slower-migrating
variant represents 10% (averages of 10 and 9%). In the sem-
inal compartment, the slower-migrating variant represents
72% (averages of 70 and 74%) of the total population and the
faster migrating variant 14% (averages of 13 and 14%). The
two other cases with multiple V1/V2 variants in the blood had
similar variant representation in the semen (Z04 and Z11). No
differences were detected in the V3 region in any of the sam-
ples (data not shown). Thus, to a large extent, variants in the
blood are found early in the semen, with some differences in
the relative proportion of V1/V2 variants.
The V1/V2 variants found in the blood plasma versus the
CSF for five subjects are shown in Fig. 8. Only subject Z10
showed any evidence of compartmentalization, with a few mi-
nor blood V1/V2 variants not detected in the CSF. The mul-
FIG. 5. V3-HTA patterns of subjects during primary HIV-1 infection. (A) Control lanes with the clade B (JN27) and clade C (JN33) V3 probes
alone or against their PCR products. The single-stranded probe is indicated by the top arrows, and the lower arrow indicates the probe
homoduplex. (B) Viral RNA from blood plasma was used as a template to amplify the V3 region of env using PCR. Heteroduplexes were formed
between the PCR product and either the pJN27 (clade B) or pJN33 (clade C) V3 HTA probes. The resulting heteroduplexes were resolved in a
polyacrylamide gel. Subject identifiers are shown at the bottom of the each lane. WPI, weeks postinfection; #, number of V3 variants detected.
FIG. 6. Phylogenetic analysis of plasma gag sequences. The se-
quence from the bulk PCR product covering two overlapping regions
of gag p17 and p24 were combined for this analysis. Subject numbers
are indicated. Branch numbers represent number of nucleotide changes
per 100 bases.
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tiple V1/V2 variants present in the three other subjects were
present in similar proportions in both the blood and CSF.
Again, no differences were detected in the V3 region (data not
shown). The lack of compartmentalization between the periph-
ery and the central nervous system suggests that during pri-
mary infection, these two compartments equilibrate relatively
quickly.
Selection of a vaccine candidate among viruses isolated dur-
ing primary infection. Significant effort is being made to de-
velop HIV-1 vaccine candidates. Although cross-subtype reac-
tivity has been demonstrated in cytotoxic T lymphocytes
(CTLs) from individuals infected with different subtypes (2, 15,
17, 35, 62), the cross-subtype reactivity is typically not as strong
as intra-subtype reactivity and frequently shows subtype pref-
erences. This observation is supported by the finding that cer-
tain CTL epitopes are better conserved within one subtype
versus across subtypes (51). To facilitate the development of a
subtype B vaccine, viral sequences from this primary infection
cohort were identified with high amino acid similarity and
identity to the subtype B consensus sequence. This strategy is
designed to identify functional viral genes that minimize the
amino acid genetic distance to extant sequences. Sequences
from a primary infection cohort by definition represent cur-
rently circulating variants and would have the advantage that
the resulting vaccine candidate will represent a currently cir-
culating transmissible variant. We have previously used this
strategy to identify subtype C vaccine candidate genes (61).
Sequences from the gag (p17 and p24) and env (V4 through
gp41) genes were obtained for subjects Z01 to Z18. Two ad-
ditional primary infection subjects from another cohort were
also included (qho515 and qho692). Sequences from these
primary infections were compared to each other and to a
collection of 123 and 133 gag and env sequences, respectively,
obtained from the Los Alamos HIV Sequence Database. Pair-
wise alignments of these regions were made, and the distribu-
tions of amino acid identity scores resulting from all pairwise
comparisons, including those for the consensus sequence, were
determined for both the translated Gag and Env (Fig. 9) se-
quence fragments.
Isolate Z04 had the highest percent identity score with the
subtype B consensus sequence in both Gag and Env. Due to
these high percent identity scores, the full-length gag and env
genes from the Z04 isolate have been cloned for use in a
FIG. 7. Comparison of V1/V2 env variants in blood and semen of
subjects during primary HIV-1 infection. Viral RNA extracted from
paired blood plasma (B) or SP (S) was used as a template to amplify
the V1/V2 region of env using PCR. Subject identifiers are above the
lane. Heteroduplexes were formed and analyzed as described in the
legend of Fig. 2.
FIG. 8. Comparison of V1/V2 env variants in blood and CSF of
subjects during primary HIV-1 infection. Viral RNA extracted from
paired blood plasma (B) or CSF (C) was used as a template to amplify
the V1/V2 region of env using PCR. Subject identifiers are above the
lane. Heteroduplexes were formed and analyzed as described in the
legend of Fig. 2.
FIG. 9. Genetic distances of sequences from viruses present in the
primary infection cohort to a large set of HIV-1 sequences. Regions of
the gag (A) and env (B) genes were amplified by RT-PCR, and the
purified PCR products were sequenced by using one of the PCR
primers. The amino acid sequence was inferred from the nucleotide
sequences. Pairwise comparisons were made for percent amino acid
identity between each sequence and the clade B consensus sequence
(E) and to a large set of HIV-1 sequences. For the large comparison,
the mean value (), the inner quartile range (box), and the entire
range (line) are shown.
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subtype B HIV-1 vaccine. These genes are derived from a
replication-competent clinical isolate that will facilitate the
testing of immune responses.
DISCUSSION
The study of transmitted virus population complexity during
early primary HIV-1 infection has been limited by the difficulty
of identifying subjects before the seeding population has sig-
nificantly evolved. Multiple factors, including mode of trans-
mission, source of inoculum, complexity of the virus popula-
tion in the donor, and recipient factors, likely affect what and
how many variants are transmitted. The conflicting results of
existing primary infection studies are likely accounted for by
the inability to control for all of these variables in the trans-
mission events of the study population. We have used the
V1/V2-HTA as a tool to evaluate the complexity of the virus
population in a well-defined primary infection cohort.
Diversification of the transmitted virus in response to HIV-
1-specific host immune responses can complicate the interpre-
tation of population diversity in primary infection studies. SIV
studies can provide temporal profiles regarding host immuno-
logical responses and thus allow one to estimate the time
required for viral diversification. SIV Env-specific neutralizing
antibodies in macaques are present 7 weeks postinfection. Di-
versification of the V1/V2 region in macaques is not detected
until after 12 weeks after mucosal infection (52). Strong HIV-
1-neutralizing antibodies have been detected 6 to 8 weeks
postinfection in humans (50). These similarities suggest the
timeframe of diversification of the V1/V2 region in macaques
and humans may be similar. Our recent study with longitudinal
samples from humans suggests V1/V2 diversification starts in
the 8- to 11-week timeframe (unpublished observations). All
but two samples in our study were obtained within this time-
frame. Thus, we believe this cross-sectional analysis of human
subjects in primary infection allows us to evaluate characteris-
tics of the virus present at the earliest time points after trans-
mission and likely represent the infecting virus. It is clear that
a delay in identifying subjects in primary infection will result in
a bias toward the detection of multiple variants as a result of
env diversification due to the humoral response. In this regard
we note that the subjects staged as most proximal to the trans-
mission event had single variants (Fig. 1 and 3). However, this
group also included most of the heterosexual transmissions to
males, which appears to favor the transmission of single vari-
ants (33) (see below).
The preponderance of studies examining HIV-1 transmis-
sion show a mostly homogeneous population. Primary infec-
tion studies have focused on env variable domains to measure
viral diversity. These variable domains are not equally diverse.
In subtype B, the V1/V2 region tends to be the most variable
while the V3 region is the most conserved of the variable
domains. When we examined the V1/V2 region during primary
infection, just 50% of subjects displayed multiple variants.
However, when the V3 region was examined, only 17% of
subjects displayed multiple variants. All subjects with multiple
V3 variants also had multiple V1/V2 variants. This suggests the
V1/V2 region can reveal more diversity in transmitted variants
than the V3 region. Therefore, we believe V1/V2 HTA is a
more robust tool for describing a complex viral population
than V3 HTA, which we have also used previously in this
context (46). The detection of multiple variants in 50% of
subjects is a minimum estimate since transmission of two vari-
ants with the same V1/V2-HTA pattern would be recorded as
a single variant. This underestimate may be corrected by also
examining diversity in the V4/V5 region. As with all primary
infection studies, the timing of infection is critical to an accu-
rate assessment of primary infection viral diversity. Underes-
timating the time since transmission can result in an overesti-
mate of the complexity of the transmitted variants since the
immune response drives the viral population to greater com-
plexity.
The phylogenetic analysis of V1/V2 clones supported the
transmission of multiple variants from a single donor. The
genetic distance between variants was too extensive to have
occurred during the time of infection. Dual infection was iden-
tified in two subjects. Subject Z25 was infected by two single
variant transmission events. Subject Z26 had genetic distances
consistent with a transmission event of a single variant trans-
mission and transmission event of multiple variants. Half (two
of four) of the subjects with multiple variants by V3-HTA were
dually infected. This suggests that diversity in the V3 region
during primary infection may serve as a useful screen in the
search for dual infections that ultimately must be identified
through sequence analysis.
Zhang et al. (66) detected a higher level of diversity in gag
versus env during primary infection by examining sequences
from DNA clones generated from these genes. By HTA, we
detected a much higher level of heterogeneity in the env gene
than implied by the Zhang et al. study (66). This difference may
be explained by the different techniques used. The HTA sam-
ples all of the genomes and templates that are present in the
PCR amplification, allowing major and minor V1/V2 popula-
tions to be evident. Detection of minor populations may be
missed when a limited number of clones are sequenced since
each genome or template is sampled as one sequence. Also,
diversification due to CTL selection likely precedes diversifi-
cation by antibody selection (which presumably drives V1/V2
diversification), and the greater gag diversity reported may
reflect the effect of the early host CTL response. In addition,
Learn et al. (30) have suggested that multiple variants are
typically transmitted but then undergo selection, resulting in a
homogeneous population. We do not observe a decrease in
V1/V2 env diversity during the early period of infection either
in this cross-sectional analysis (Fig. 3) or in longitudinal studies
in macaques (52).
Several studies have shown that R5 variants are most often
transmitted, although X4 variants can be transmitted (59). Our
observation of one infection with an X4 variant is consistent
with this infrequent occurrence. The low transmission fre-
quency of X4-like virus in this cohort was similar to the 3%
frequency found in a larger UCSD cohort (99 subjects) (K.
Ritola, R. Swanstrom, D. Richman, and S. Little, unpublished
data). The low viral diversity in the V3 region and high prev-
alence of R5-like variants support the transmission of low
complexity R5-like V3 variants but do not resolve the nature of
the apparent bias for transmission of R5 over X4 variants.
Multiple models could account for our observations of pri-
mary infection diversity. Transient periods of hyperinfectious-
ness in the donor or hypersusceptibility in the recipient, the sex
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of the recipient, or the transmission of virus through infected
cells could all explain the presence of multiple V1/V2 variants.
If the infection inoculum represents cell-free virus, then, using
the Poisson distribution, the probability of infection would
have to approach 1 to give the pattern of 1 versus 2 versus 3
variants seen in this cohort. This probability of infection is or-
ders of magnitude greater than current estimates (5, 18, 22, 58).
Long et al. (33) have proposed a link between the sex of the
newly infected person and the number of variants transmitted.
They examined the diversity in the V1/V2 and V3 regions in a
primary infection cohort of heterosexually infected men and
women in Kenya. Transmission of multiple variants was evi-
dent in 63% of the females, whereas no males were found to
harbor multiple variants. They concluded that the sex of the
recipient is the primary determinant of the number of variants
transmitted. However, in our study we did not observe exclu-
sive transmission of single variants in homosexual men.
We found that 12 of 18 (67%) men harbored multiple vari-
ants after homosexual transmission events. In contrast, none of
five men infected through heterosexual contact harbored mul-
tiple variants, while one of two women had multiple V1/V2
variants, a finding consistent with the study by Long et al. (33).
These data apparently contradict the model that the gender of
the recipient is the principal determinant of initial viral diver-
sity in HIV-1 infection. An alternative hypothesis may explain
both our own observations and those of Long et al. (33). First,
it may be the characteristics of the exposed mucosal surface
that determine the initial diversity of the infecting virus pop-
ulation. Both rectal and vaginal mucosal surfaces contain no
keratinized epithelium and hence provide an infecting inocu-
lum with a different environment than does the penile skin. We
propose that the involvement of the recipient’s mucosal sur-
face greatly increases the likelihood that infected cells partic-
ipate in transmission. In this model, women would typically
transmit single variants to men, while men would typically
transmit multiple variants to women or men.
Transmission solely by cell-free virus in the context of low
transmission probabilities should result in the presence of sin-
gle variants much more frequently than multiple variants. This
is inconsistent with our observation that homosexual transmis-
sion more frequently results in the transmission of multiple
variants. Transmission via infected cells in semen could ac-
count for both the transmission of multiple variants and the
observation that transmission is a low-frequency event. Zhu
et al. (68) have previously shown that seminal cells can be
the source of infecting virus. Jung et al. (24) have shown that
HIV-1-infected spleen cells each harbor between 1 to 8 provi-
ruses, with an average 3.2 proviruses per cell. These numbers
are consistent with our data for the number of variants trans-
mitted from a seminal inoculum. There was a range of one to
five variants, with an average of two variants per subject. In this
model, the rare transmission event from semen can involve a
single infected cell that contains multiple viral variants initiat-
ing the new infection.
The presence of virus in the central nervous system and
the seminal compartment has been well documented during
chronic and end-stage infection. Our data indicate that these
compartments are quickly populated by the infecting strain, at
least as measured by V1/V2-HTA and V3-HTA. During acute
primary infection, predominantly the same viral variants were
detected in the periphery and the CSF and/or SP, suggesting
that these variants rapidly and efficiently enter these compart-
ments. Evidence for some early compartmentalization was de-
tected in two subjects: in the SP of Z03 and in the CSF of Z10.
These differences could be the result of different rates of pen-
etration or expansion between the compartments. The pres-
ence of identical R5-like variants in the periphery and CSF
supports the macrophage-tropic requirement for central ner-
vous system infection described by Gorry et al. (21). Viral
variants apparently become compartmentalized later during
the course of infection.
There is some interest in considering primary infection iso-
lates as vaccine candidates, especially given the possibility that
they may have distinctive properties (13). We have previously
used a sequence survey approach of subtype C HIV-1, primary
infection subjects to identify vaccine sequences near the con-
sensus sequence (61). Given that CTL epitopes tend to be
more conserved within a subtype (51), it may be useful to
develop subtype-specific vaccines. To this end, we have iden-
tified isolate Z04 as having a sequence profile close to that of
the subtype B consensus (Fig. 9). Although this does not rep-
resent a consensus sequence, it does allow the use of viral
genes derived from a replication competent isolate that will not
represent an outlier among the currently circulating subtype B
viral sequences.
In conclusion, we have shown that the V1/V2-HTA repre-
sents a useful tool to assess the viral diversity present during
primary infection and that multiple variants are frequently
present. We hypothesize that the sex of the transmitter and the
nature of the exposed mucosal surface rather than the sex of
the recipient influences the number of variants transmitted,
with multiply infected cells in semen playing an important role
in transmission. Compartmentalization between the periphery
and the seminal or central nervous system compartment is not
evident during primary infection and therefore must develop
as the infection progresses. The potential role of a multiply
infected cell in transmission events may have important impli-
cations for the design of a vaccine and/or a microbicide.
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